Jan 11, 2022 8:30am EST Artelo Anticipates Accelerated Clinical Development for ART27.13 Following Its Classification Change in the United Kingdom
Jan 10, 2022 9:00am EST Artelo Biosciences Leadership to Participate on Endocannabinoid Panel at the H.C. Wainwright BioConnect 2022 Virtual Conference
Nov 29, 2021 8:30am EST Artelo Biosciences Reports Fiscal 2021 Year-End Financial Results and Provides Business Update
Sep 08, 2021 8:30am EDT Artelo Biosciences to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Aug 11, 2021 7:30am EDT Artelo Biosciences to Present at the Q3 Virtual Investor Summit on August 18th
Aug 04, 2021 8:30am EDT Artelo Biosciences Announces Publication of Study Results Comparing the Pharmacological Effects of Plant-Derived Versus Synthetic Cannabidiol in Human Cell Lines
Jul 21, 2021 8:30am EDT Ladenburg Thalmann to Host R&D Showcase Featuring Artelo Biosciences’ CAReS Study on July 28, 2021
Jul 12, 2021 8:30am EDT Artelo Biosciences Reports Third Quarter Fiscal 2021 Financial Results and Provides Business Update
Jul 07, 2021 8:30am EDT Artelo Biosciences to Present at the 2021 Ladenburg Thalmann Healthcare Conference on July 14th
